MONISTAT DUAL- PAK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MONISTAT DUAL- PAK (MONISTAT DUAL- PAK).
Miconazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, reducing ergosterol synthesis and disrupting fungal cell membrane integrity. Tioconazole, also an imidazole, similarly inhibits ergosterol synthesis.
| Metabolism | Miconazole is primarily metabolized by hepatic CYP3A4; tioconazole undergoes hepatic metabolism, but specific enzymes not fully characterized. |
| Excretion | Approximately 90% of an absorbed dose is eliminated in feces as unchanged drug and metabolites; less than 1% is excreted renally as unchanged drug. Biliary excretion is the primary route for the absorbed fraction. |
| Half-life | The terminal elimination half-life of miconazole following intravenous administration is approximately 24 hours (range 20-30 hours). This supports once-daily dosing for systemic infections, though topical application yields negligible systemic absorption. |
| Protein binding | Approximately 88-93% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 20 L/kg (1400 L for a 70 kg adult), indicating extensive tissue distribution and accumulation in adipose tissues. |
| Bioavailability | Vaginal absorption: 1.4-5.5% of a 200 mg suppository dose is systemically absorbed. Topical cream: <1% absorbed through intact skin. Oral bioavailability is negligible (<1%) due to poor gastrointestinal absorption. |
| Onset of Action | Vaginal suppository: Relief of symptoms typically begins within 1-3 days. Topical cream: Pruritus and irritation may improve within 24-72 hours. Systemic effects are irrelevant due to minimal absorption. |
| Duration of Action | Vaginal suppository: Single-dose therapy provides therapeutic concentrations for 3-7 days. Topical cream: Twice-daily application maintains effect for 7 days; clinical cure expected within 7-14 days. |
Intravaginal: One applicatorful of 6.5% miconazole nitrate cream (1200 mg) at bedtime as a single dose. Topical: Apply 2% miconazole nitrate cream to affected area twice daily for 2 weeks.
| Dosage form | CREAM, SUPPOSITORY |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for mild to moderate hepatic impairment; use with caution in severe impairment due to limited data. |
| Pediatric use | Intravaginal use not recommended for prepubertal children. Topical: Apply 2% cream twice daily for 2 weeks for children ≥2 years; safety and efficacy for children <2 years not established. |
| Geriatric use | Same as adult dosing; no specific adjustments required, but consider potential for mucosal irritation and ensure proper administration. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MONISTAT DUAL- PAK (MONISTAT DUAL- PAK).
| Breastfeeding | Miconazole is poorly absorbed systemically after vaginal administration. Excretion into breast milk is negligible. The M/P ratio is not determined due to minimal systemic absorption. Compatible with breastfeeding; wash hands after application to avoid infant contact. |
| Teratogenic Risk | Miconazole is considered low risk during pregnancy. No increased risk of malformations or adverse fetal outcomes has been reported in epidemiologic studies for topical/vaginal use. First trimester: data limited but no clear teratogenic signal. Second and third trimesters: generally considered safe; systemic absorption from vaginal use is minimal (<2%). Category C (pre-2015 FDA). |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to miconazole, tioconazole, or any component","Pregnancy (intravaginal application may increase risk of congenital anomalies; use only if clearly needed)"]
| Precautions | ["Hypersensitivity reactions","Increased risk of bleeding with concurrent warfarin use due to CYP2C9/CYP3A4 inhibition","Monitor for signs of hepatotoxicity","Not for systemic fungal infections"] |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring required. Monitor for local adverse effects (e.g., irritation, burning). If symptoms persist or recur, confirm diagnosis and exclude other pathogens. |
| Fertility Effects | No known adverse effects on fertility. Miconazole does not impair reproductive function in animal studies. No human data indicate negative impact on fertility. |